Reviewer's report

Title: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. I: analysis of cases.

Version: 1 Date: 12 March 2010

Reviewer: David M Taylor

Reviewer's report:

This is an important and excellent paper with which I can find no fault. No revisions required.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

Professor Taylor has received consultancies fees, lecturing honoraria and/or research funding from AstraZeneca, Janssen-Cilag, Servier, Sanofi-Aventis, Lundbeck, Bristol-Myers Squibb, Novartis, Eli Lilly and Wyeth.